Company / Cash & Equivalents
LifeMD, Inc. Cash & Equivalents History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$35.0M
FY2024
5-year range
$4.0M / $41.3M
FY2020-FY2024
Trend
+5.6%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 9 years, ranging from $75,495 in FY2016 to $41M in FY2021.
Based on SEC 10-K filings.
$35M in FY2024 with a 5-year CAGR of +99.5%.
Improved from $4M to $35M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -5.4%
- 5-Year CAGR
- +99.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +99.5%, indicating consistent growth.
- In FY2024, cash & equivalents increased 5.6% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $35.0M | +5.6% |
| FY2023 | $33.1M | +737.3% |
| FY2022 | $4.0M | -90.4% |
| FY2021 | $41.3M | +350.2% |
| FY2020 | $9.2M | +729.5% |
| FY2019 | $1.1M | +682.7% |
| FY2018 | $141.4K | -39.3% |
| FY2017 | $233.0K | +208.6% |
| FY2016 | $75.5K | +0.0% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026